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Abstract
Background: Leukocyte Function Antigen-1 (LFA-1) is a primary adhesion molecule that plays
important roles in T cell activation, leukocyte recirculation, and trans-endothelial migration. By
applying a multivariate intracellular phospho-proteomic analysis, we demonstrate that LFA-1
differentially activates signaling molecules.
Results: Signal intensity was dependent on both ICAM ligand and LFA-1 concentration. In the
presence of CD3 and CD28 stimulation, ICAM-2 and ICAM-3 decreased TGFβ1 production more
than ICAM-1. In long-term differentiation experiments, stimulation with ICAM-3, CD3, and CD28
generated IFNγ producing CD4+CD45RO+CD62L-CD11aBrightCD27- cells that had increased
expression of intracellular BCL2, displayed distinct chemokine receptor profiles, and exhibited
distinct migratory characteristics. Only CD3/CD28 with ICAM-3 generated
CD4+CD45RO+CD62L-CD11aBrightCD27- cells that were functionally responsive to chemotaxis
and exhibited higher frequencies of cells that signaled to JNK and ERK1/2 upon stimulation with
MIP3α. Furthermore, these reports identify that the LFA-1 receptor, when presented with multiple
ligands, can result in distinct T cell differentiation states and suggest that the combinatorial
integration of ICAM ligand interactions with LFA-1 have functional consequences for T cell biology.
Conclusion:  Thus, the ICAM ligands, differentially modulate LFA-1 signaling in T cells and
potentiate the development of memory human T cells in vitro. These findings are of importance in
a mechanistic understanding of memory cell differentiation and ex vivo generation of memory cell
subsets for therapeutic applications.
Background
Leukocyte Function Antigen-1 (LFA-1), an αβ het-
erodimer integrin, is necessary for leukocyte adhesion and
migration and is important in the formation of the immu-
nological synapses [1-3]. LFA-1 also has prominent roles
in T cell costimulation [4,5] and transendothelial migra-
tion [6]. The LFA-1 ligands, intracellular adhesion mole-
cules (ICAMs) -1, -2, and -3, differentially bind to LFA-1
and regulate its adhesion [7-9]. LFA-1 is a mediator of T
cell driven inflammatory diseases such as psoriasis[10],
rheumatoid arthritis[11], and multiple sclerosis [12], and
is a pharmaceutical target for the prevention of the rejec-
tion of organ transplantation [13].
Peripheral blood lymphocytes (PBLs) primarily express
LFA-1 as opposed to the other beta-2 integrins, such as
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MAC-1 (CD11b/CD18) and p150,95 (CD11c/CD18),
and serves as a primary adhesive molecule for T cells.
However, natural killer (NK) cells, eosinophils, neu-
trophils, monocytes, and dendritic cells also express LFA-
1 and other integrins. Impairment of LFA-1/ICAM interac-
tions, using monoclonal antibodies or in LFA-1 knockout
mice, disrupts adhesion and migration of neutrophils,
monocytes, eosinophils, and NK cells in several disease
models of inflammation. Pathologies in these models
include thioglycollate-induced peritonitis, delayed
delayed-type hypersensitivity, asthma, and susceptibility
to bacterial and viral infection [14-16].
Significant advances have been made in understanding
the structural properties of LFA-1 and the conformational
states that LFA-1 adopts upon ligand binding [17-19].
However, it is not clear how LFA-1 governs interactions in
the context of multiple ligands or if LFA-1 signaling mech-
anisms are similar in different cell types. Previously, we
showed that LFA-1 transmitted distinct intracellular sign-
aling events that, in the presence of CD3 and CD28 stim-
ulation, enhanced T cell activation thresholds and
polarized T cells towards IFNγ-producing effector
cells[20]. Since human effector T cells differentiate into
memory T cells, and LFA ligands are known to be impor-
tant for enhancing the interaction at the immunological
synapse, we investigated how the three endogenous LFA-
1 ligands influenced commitment of human T cells to
adopt a TH1 memory phenotype. In particular, it is of
interest as to whether the combinatorial integration of sig-
naling induced by LFA-1's interactions with its ligands
achieved an internal signaling threshold that committed T
cells to end-fate decisions such as differentiation into a
particular memory cell subset.
We find that the ICAM ligands differentially promote cell
survival. In the presence of CD3 and CD28, stimulation
with either ICAM-2 or ICAM-3 suppressed activation of
caspase-3. Phospho-proteomic profiling showed that p38
and p44/42 phosphorylation was enhanced and rate of
activation was increased. Production of TGFβ1 was
decreased when cells were treated with CD3/CD28 plus
ICAM-2 or ICAM-3, but not ICAM-1, indicating that dif-
ferent ICAMs can alter cytokine production that can influ-
ence TH1/TH2 T cell development. In long-term
differentiation experiments, CD3/CD28 plus ICAM-3 or
ICAM-2 generated a higher frequency of IFNγ producing
CD4+CD45RO+CD62L-CD11aBright  cells than stimula-
tion with ICAM-1. Only ICAM-3/CD3/CD28 stimulation
resulted in differentiation to the CD4+CD45RO+CD62L-
CD11aBrightCD27- phenotype that transmigrated in
response to chemokines. Upon stimulation with MIP3α,
the highly differentiated CD4+ memory T cells that were
generated by ICAM-3/CD3/CD28 produced a higher fre-
quency of phospho-p44/42 and phospho-JNK positive
cells than those stimulated with the other ICAMs, indicat-
ing a functionally responsive CD4+ memory cell subset.
These results suggest that signal activation thresholds for
CD4+ memory T cell differentiation are integrated with,
and bounded by, the combinatorial integration of input
signals of CD3, CD28 and LFA-1. However, only ICAM-2
and ICAM-3 showed important responses to the produc-
tion of highly differentiated functional memory CD4+ T
cells in vitro. T cell commitment drives many adaptive
immune system processes and thus these results are rele-
vant to situations where multiple ligands interact with a
single receptor to drive different underlying processes. The
analysis shown here demonstrates that it is possible to dis-
tinguish these events at the single cell level.
Results
Stimulation of LFA-1 with ICAM-2 or ICAM-3 in the 
presence of CD3/CD28 co-stimulation does not activate 
caspase-3
Clonal expansion following T-cell antigen receptor (TCR)
stimulation results in T cell activation, cellular division,
and under certain circumstances the initiation of activa-
tion-induced cell death (AICD)[21,22]. We investigated
the effects of the three major LFA-1 ligands on their capac-
ity to enhance cell survival. For these assays, ligand/anti-
body absorption was optimized on positively charged
polystyrene surface 96-well plates to orient globular Ig
structures in the proper orientation (see Methods). Addi-
tionally, all ligands for stimulation were used as FC con-
structs for proper orientation. Naïve CD4+ T cells were
stimulated with increasing doses of CD3/CD28 in the
presence of the different ICAMs. Naive T cells were stimu-
lated with ICAM-1, ICAM-2, ICAM-3, CD3, CD3/CD28
(1:1 protein ratio), ICAM-1/CD3/CD28, ICAM-2/CD3/
CD28, or ICAM-3/CD3/CD28 (1:1:1 protein ratio) coated
plates at 10, 100 and 1000 ng, and were monitored for the
intracellular activation of caspase-3 by flow cytometry at
24 hrs. Stimulation with ICAM-1, ICAM-2 or ICAM-3
alone did not induce caspase-3 activation (Fig. 1A). CD3
and CD3/CD28 alone induced a concentration depend-
ent increase in activated caspase-3, which was similar to
CD3/CD28 plus ICAM-1 (Fig. 1A). CD3/CD28 in the
presence of ICAM-2 or ICAM-3 stimulation did not acti-
vate caspase-3 (Fig. 1A) at any of the tested concentrations
at 24 hours. We confirmed these results using a cytometric
bead array to measure active caspase-3 at 24, 48, and 72
hrs (Fig. 1B). The expected activation of caspase-3 after
CD3 or CD3/CD28 stimulation was observed (Fig. 1B). In
the presence of CD3 and CD28, ICAM-2 stimulation
resulted in lower levels of active caspase-3 at the 48 and 72
hr time points than ICAM-1 or ICAM-3 stimulations (Fig.
1B).BMC Immunology 2007, 8:2 http://www.biomedcentral.com/1471-2172/8/2
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Stimulation of LFA-1 through ICAM-2 and ICAM-3 in the presence of CD3/CD28 co-stimulation does not activate caspase-3 Figure 1
Stimulation of LFA-1 through ICAM-2 and ICAM-3 in the presence of CD3/CD28 co-stimulation does not acti-
vate caspase-3. (A) Intracellular staining of cleaved-caspase 3 in cells treated with ICAM-1, ICAM-2, ICAM-3, CD3, CD3/
CD28, CD3/CD28/ICAM-1, or CD3/CD28/ICAM-2, or CD3/CD28/ICAM-3. Naïve T cells were stimulated in 96-well coated 
plates and stained for CD4-PercpCy5.5 and intracellular cleaved-caspase-3-PE at 24 hrs. Data is representative of triplicate 
measures from one donor. Similar results were observed across three donors. (B) Cytometric bead array assessment of 
cleaved caspase-3 at 24, 48, and 72 hrs after naïve T cells were stimulated with 10, 100, 1000 ng of ICAM-1, ICAM-2, ICAM-3, 
CD3, CD3/CD28, ICAM-1/CD3/CD28, ICAM-2/CD3/CD28, or ICAM-3/CD3/CD28. Results are averaged from triplicate 
assays from three donors. Insert displays standard deviation for 48 hour measurement as denoted by the asterisk. (C) Absolute 
counts of cell divisions of naïve T cells stimulated with CD3/CD28 (control) or in the presence of TS1/22, ICAM-1, ICAM-2, or 
ICAM-3. T cells were labeled with CMFDA, stimulated in coated 96-well plates, and analyzed at day 7. TruCount beads were 
used to determine absolute viable cell numbers of divisional peaks detected by CMFDA fluorescence. Assays were performed 
on 6 individual donors. Triplicate measures from one donor are displayed in insert.
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We investigated whether the reduced cell death induced
by ICAM-2/CD3/CD28 correlated with enhanced cellular
division. Purified, naïve CD4+ T cells were labeled with 5-
chloromethylfluorescein diacetate (CMFDA) and were
incubated on CD3/CD28 coated plates in the presence of
equivalent amounts of CD3/CD28, ICAM-1/CD3/CD28,
ICAM-2/CD3/CD28, ICAM-3/CD3/CD28, or CD3/CD28
plus LFA-1 antibody TS1/22 and were monitored for
seven days. We quantified the absolute cell counts in each
of the cell cycle divisions using TruCount beads in order
to quanitate the viable cells and compare the effect of
ICAM stimulation to that of LFA-1 antibody stimulation.
A greater numbers of cells in samples treated with CD3/
CD28 plus ICAM-2 and CD3/CD28 plus ICAM-3 under-
went three cell divisions than cells in samples treated with
CD3/CD28 in the presence of ICAM-1, TS1/22, or control
(CD3/CD28 alone) (Fig. 1C). The lower numbers of cells
entering the third cell cycle division for CD3/CD28 plus
ICAM-1, TS1/22, and control samples correlated with
higher cell death numbers in those treatments (Fig. 1C).
These observations support the notion that the different
ICAM ligands induce different cell division and death
responses upon LFA-1 engagement in vitro. Conse-
quently, the results suggest that LFA-1 signaling can inte-
grate with that of CD3/CD28 to enhance proliferation
and promote cell survival when stimulated with the
appropriate ligand.
LFA-1 transmits intracellular signals that integrate with 
those of CD3 and CD28
Given that LFA-1 adhesion is an important determinant of
outcome at the immunological synapse, we surveyed sig-
naling molecules that serve as points of signal integration
with TCR signaling. To identify a nodal point of signal
crosstalk between LFA-1 and CD3/CD28, we evaluated
the phospho-signature profiles of all three ICAM ligands
in the presence of CD3 and CD28. We quantified the
phosphorylation status of T cell signaling molecules
PLCγ1, Lck, Zap70/Syk, p38, and p44/42 as a function of
ligand concentration and time of stimulation by multipa-
rameter flow cytometry (Fig. 2A). We performed both
dose and kinetic response analysis to determine stimula-
tion-specific differences. Although rates of phosphoryla-
tion were dependent on concentration of ligand as
expected, we did not observe significant differences for
proximal signaling molecules such as Lck, Zap70, or
PLCγ1 (data not shown). At 5 minutes, phosphorylation
of p38 was observed to be increased in a dose-dependent
manner in ICAM-2/CD3/CD28 and ICAM-3/CD3/CD28
treated samples but not other treatments (Fig. 2B), but no
stimulation-specific effect was observed for phosphoryla-
tion of Zap70 (Fig. 2C), suggesting that initial kinetics of
signal transduction to MAPK proteins was affected differ-
entially by the ICAM ligands. At longer time points, phos-
phorylation levels of p38 saturated to similar levels in all
CD3/CD28 treatment groups (data not shown).
We evaluated the phosphorylation levels of ERK1/2, a
kinase essential for T cell activation. Using a ratiometric
assay, we measured the levels of intracellular phosphor-
ylated and non-phosphorylated Erk1/2 in populations of
T cells stimulated with CD3/CD28 and the ICAM ligands.
This assay provides a single cell based quantitative meas-
urement to assess signaling thresholds of ERK1/2. We
computationally derived the ratio of the two antibody
stains in CD4+ T cells and used statistical algorithms to
compare the treatment populations (Fig. 2D). We utilized
four different comparison algorithms to determine
whether the addition of the ICAM ligands resulted in a sta-
tistically significant difference compared to the CD3/
CD28 stimulation (Fig. 2D). Two algorithms, the Overton
cumulative histogram subtraction algorithm and the
Super-enhanced Dmax subtraction (SED), calculate the
percentage of positive cells found in the treatment groups
relative to the control[23]. More positive cells were found
in samples treated with ICAM ligands than CD3/CD28
alone (Fig. 2D). The probability binning (Chi(T)) algo-
rithm was used to compare the ratio of phospho-ERK1/2
to non-phospho-ERK1/2 in samples treated with ICAM
ligands to the control[24,25]. This algorithm can detect
small differences between two populations. A value of
T(X) > 4 implies that the distributions are different with a
p value < 0.01[24,26]. The Chi(T) metric T(X) was 3.8 for
the ICAM-1/CD3/CD28 treatment, 34.7 for the ICAM-2/
CD3/CD28 treatment, and 43.6 for the ICAM-3/CD3/
CD28 treatment (Fig. 2D). Therefore, the ICAM-2 and
ICAM-3 treatments had ratios of phospho-ERK1/2 to non-
phospho-ERK1/2 that were statistically different than that
of CD3/CD28 alone. In the presence of CD3/C28, all
three ligands induced phospho-ERK1/2 signaling
responses over the course of 30 minutes. However, there
were differences in both the kinetics and signal intensity
of the phosphorylation, supporting our prior findings that
LFA-1 can signal to ERK1/2 [20]. These results suggest that
p38 and ERK1/2 are two signaling nodes where signal
integration from different cell surface receptors occurs.
The differences in observed signaling thresholds with
ICAM-1 could be correlated with a lack of T cell differen-
tiation (see below).
Differential capacity of the ICAM ligands to promote 
CD45RO+ memory cell differentiation
Since LFA-1 signaling can promote early effector cell gen-
eration of TH1 cells[20], we tested whether the observed
differences in signaling thresholds of the ICAM ligands
had functional consequences in the long-term differentia-
tion of naïve CD45RA+ T cells to memory CD45RO T
cells. We plated naïve CD4+ CD45RA+ T cells on CD3/
CD28 coated plates in the presence of equivalent amountsBMC Immunology 2007, 8:2 http://www.biomedcentral.com/1471-2172/8/2
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Phospho-epitope profiling of signaling cascades upon LFA-1 signaling Figure 2
Phospho-epitope profiling of signaling cascades upon LFA-1 signaling. (A) Graphical representation of screening 
strategy. (B) 250,000 naïve CD4+ T cells were crosslinked with CD3 (mAb UCHT1), CD28 (clone 28.2) or ICAM ligand on U-
bottom plates for 5, 10, 15, 30 minutes. Adherent cells were fixed, permeabilized, and stained for phospho-epitopes. Data val-
ues are relative to non-adherent control cells and were computed using Spotfire software. Data is displayed as a scattered plot 
profile as a function of the concentration of stimulation agent. Data is averaged from triplicate measures from four individual 
donors. (C) Phospho-proteomic analysis of p38 and zap70 after 5 minutes stimulation at 1000 ng ligand. Data was computed as 
the ratio of stimulated to unstimulated cells. Error bars are computed from triplicates. (D) Ratiometric measure of intracellular 
phosphorylated-p44/42 and pan-p44/42 as a function of CD3/CD28, ICAM-1/CD3/CD28, ICAM-2/CD3/CD28, or ICAM-3/
CD3/CD28 stimulation (1000 ng) after 15 minutes. Cells were stimulated in 96-well coated plates and then stained with CD4-
PercpCy5.5, phospho-p44/42-PE, and pan-p44/42-AX680. Quantitation of the ratio of phospho-p44/42 to pan-p44/42 was 
computed in Flowjo. The data is representative from triplicate experiments. The experiment was performed using cells from 
two donors.
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of ICAM-1, ICAM-2, ICAM-3, or α-LFA-1, or combina-
tions of ICAM1/ICAM-2, ICAM-2/ICAM-3, or ICAM-1/
ICAM-3. Over the course of 14 days, we monitored
CD45RA and CD45RO expression and live/dead cell dis-
crimination by PI and Annexin-V stain. The data was vis-
ualized by generation of heatmaps to facilitate pattern
recognition. Following stimulation with CD3/CD28
alone a small percentage of cells differentiated to
CD45RO+ T cells, but the majority of the cells remained
in a CD45RA+CD45RO+ state (Fig. 3, panel 1). Exposure
to the α-LFA-1 monoclonal antibody (TS1/22) blocked
CD45RA+ progression into the subsequent stages (Fig. 3,
panel 2).
However, important differences were observed after stim-
ulation with ICAM-1, ICAM-2, and/or ICAM-3 in the pres-
ence of CD3/CD28 co-stimulation. Cells stimulated with
ICAM-1/CD3/CD28 progressed to the
CD45RA+CD45RO+ stage, but there was a slight increase
in detected Annexin-V staining and a decrease in percent-
age of remaining live cells as compared to cells stimulated
with CD3/CD28 only (Fig. 3, panel 3). This however is
less than 10% and considered to be in the range of back-
ground for apoptotic assays. Few cells progressed to the
CD45RO+ stage upon ICAM-1 or ICAM-3 stimulation.
Cells stimulated with ICAM-2/CD3/CD28 differentiated
to the CD45RO+ stage (Fig. 3, panel 4). Therefore, differ-
ent LFA-1 ligands resulted in important phenotypic out-
comes during in vitro progression from CD45RA to
CD45RO.
When tested in combination, the ICAMs also showed
interesting dominant, synergistic or non-intuitive out-
comes. For instance, the combination of ICAM-2 with
ICAM-1 in the presence of CD3/D28 enabled the progres-
sion to CD45RO+ differentiation, with an apparent dom-
inance of ICAM-2 over ICAM-1 (Fig. 3, panel 5). In
contrast, cells treated with ICAM-1/CD3/CD28 did not
progress past the CD45RA+CD45RO+ stage (Fig. 3, panel
3). Paradoxically, even though individually ICAM-2 and
ICAM-3 in the presence of CD3/CD28 gave the best sign-
aling in our tests of Erk1/2 activation and promoted cell
survival, stimulation with both ICAM-3 and ICAM-2 in
the presence of CD3/CD28 reduced the frequency of
CD45RO+ cells compared to cells stimulated with CD3/
CD28 only and blocked progression at the CD45RA+
stage (Fig. 3, panel 6). The combination of ICAM-1 and
ICAM-3 with CD3/CD28 also increased the percentage of
CD45RO+ cells relative to CD3/CD28 treatment (Fig. 3,
panel 7). Thus engagement of LFA-1 with multiple ligands
on the same T cell is not the same and leads to critically
different biologic outcomes during T cell differentiation.
Given the spatial and temporal distribution of ICAM
expression on hematopoetic and non-hematopoetic tis-
sues such as endothelium, the activation of T cells at sites
of inflammation where ICAMs are upregulated may be
modulated by competitive ICAM ligands.
Since long-term differentiation requires blockade of cell
death programs, we sought to evaluate the intracellular
levels of BCL-2, an anti-apoptotic molecule, after a 7 day
differentiation period. Expression of intracellular BCL2
was more prominent in CD4 T cells stimulated with the
ICAM ligands and CD3/CD28 after 7 days than cells stim-
ulated with CD3/CD28 only; cells stimulated with ICAM-
3 exhibited highest levels of BCL2 expression (Fig. 4A).
These results corroborate the enhanced early clonal
expansion and promotion of cell survival at early stages of
activation (Fig. 1) and thus illustrate that the ICAMs can
differentially potentiate CD3/CD28 signaling,
We then determined the specific functional differences in
the differentiated CD4+ T cells as mediated by the ICAM
ligands. Higher frequencies of IFNγ-producing T cells were
observed after 7 days in populations treated with ICAM-2/
CD3/CD28 or ICAM-3/CD3/CD28 than samples treated
with ICAM-1/CD3/CD28 (Fig. 4B). These differences were
also observed with extracellular production of IFNγ (data
not shown). Therefore, although all stimulations of the
ICAMs with CD3/CD28 could promote production of the
TH1 cytokine IFNγ, there were differences in the ICAMs
stimulatory capacity to generate IFNγ producing T cells.
To examine the repetoire of cytokine production as
induced distinctly by the ICAM ligands, we profiled the
production of 25 cytokines from purified naïve T cells
stimulated with CD3/CD28 in the presence of each of the
three ICAM ligands over the course of 14 days. It was
observed that production of TGFβ1 was diminished when
CD3/CD28 was combined with ICAM-2 and to a lesser
degree ICAM-3, but not ICAM-1 (Fig. 4C). This was con-
firmed using T cells from different donors (data not
shown). Since TGFβ1 blocks T cell proliferation and dif-
ferentiation[27,28], the significance of these results could
be linked to the generation of functionally distinct T cell
memory subsets, a conclusion supported by our observa-
tions in Fig. 3, and explored below.
Generation of CD45RO+ memory T cell subsets with 
distinct phenotypic and functional characteristics upon 
stimulation with different ICAM ligands and CD3/CD28
Different ICAM ligands generated phenotypically distinct
subsets of CD45RO+ T cells in vitro (Fig. 3). We first
assessed the expression of CD27 and CD11a to classify
memory T cells into CD4+CD45RO+CD11abright,
CD4+CD45RO+CD11adim, and into
CD4+CD45RO+CD11abrightCD27- memory T cells. Four
differentiation markers have been shown to accurately
reflect memory T cell subsets [29]. After a 14 day differen-
tiation period, we quantified the CD45RO+ cells express-BMC Immunology 2007, 8:2 http://www.biomedcentral.com/1471-2172/8/2
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ing CD27 or CD11a as these markers stratify the
CD45RO+ cells into memory T cell subsets. Fig. 5A illus-
trates that the CD45RO+CD11abright population is gener-
ated to a greater extent in CD3/CD28 plus ICAM-2 or
ICAM-3 at both the 100 ng and 1000 ng stimulation dose
than CD3/CD28 plus ICAM-1 or CD3/CD28 alone (red
starred quadrants). Quantifying for absolute cell counts,
we observed a greater frequency of CD45RO+CD11abright
T cells, a highly differentiated subset, in samples treated
with CD3/CD28 plus ICAM-3 than other treatment
groups, particularly at 1000 ng of ICAM-3 (Fig. 5B). Phe-
notyping these cells for CD27, an antigen lost during dif-
ferentiation of naive T cells to highly differentiated
memory T cells, showed that only cells stimulated with
CD3/CD28 plus ICAM-2 or CD3/CD28 plus ICAM-3 lost
CD27 expression (Fig. 5C). These results suggest that the
highly differentiated CD4+ T memory cell subset
(CD45RO+CD11abrightCD27-) was best generated upon
long-term stimulation with CD3/CD28 plus ICAM-3.
This phenotypic analysis was extended to survey a panel
of chemokine receptors as chemokine receptors have been
recently identified as surrogates of unique terminally dif-
ferentiated subsets [30]. Of the receptors surveyed,
CXCR3 exhibited ICAM specific stimulation expression
(Fig. 6A). The frequency of generated
ICAM-1, ICAM-2, and ICAM-3 differentially promote memory cell development Figure 3
ICAM-1, ICAM-2, and ICAM-3 differentially promote memory cell development. Progression of naïve to memory 
cell differentiation was monitored by immunophenotyping of CD45RA, CD45RO in CD4+T cells over 14 days, with full 
CD45RO development observed by ICAM-2 stimulation in the presence of CD3/CD28. 5 × 106 naïve CD4+ T cells were 
plated on 96-well plates coated with CD3/CD28 (control) or CD3/CD28 in the presence of α-LFA-1 antibody (clone TS1/22), 
ICAM-1, ICAM-2, ICAM-3, or combinations of ICAMs (as indicated). Cells were stained with CD45RA-PE, CD45RO-
Cychrome, Annexin-FITC, and PI on days 1, 3, 5, 7, 9, 12, and 14. TruCount beads were used to obtain absolute cell counts. 
Data was computed and compiled using TreeView software for pattern recognition. The color intensities are averaged from 
triplicate experiments and each row represents an individual donor. Triplicate data for each of the three donors is displayed 
per stimulant. The experiment was repeated with naïve T cells from six donors.
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Distinct functional properties of naïve CD4 T cells stimulated by ICAM ligands in the presence of CD3/CD28 Figure 4
Distinct functional properties of naïve CD4 T cells stimulated by ICAM ligands in the presence of CD3/CD28. 
(A) Intracellular expression of BCL-2 following stimulation of naïve CD4+ T cells with CD3, CD3/CD28, ICAM-1/CD3/CD28, 
ICAM-2/CD3/CD28, or ICAM-3/CD3/CD28. Mean values for fluorescent intensity are indicated by the histogram. Assay was 
performed in triplicates from four donors. (B) Frequency of IFNγ producing CD4+T cells after 7 days of stimulation with CD3/
CD28, ICAM-1/CD3/CD28, ICAM-2/CD3/CD28, or ICAM-3/CD3/CD28. Assay displays standard deviation from triplicate 
measurements and was repeated in T cells from 4 different donors. (C) Secreted production of TGFβ1 after 48 hours of stim-
ulation. Graph displays standard deviation from triplicate experiments from two different donors. tTest calculations were per-
formed and indicated in the table insert, with p < 0.05 being significant
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Distinct phenotypes of CD45RO+ memory T cell subsets generated upon stimulation with different ICAM ligands and CD3/ CD28 Figure 5
Distinct phenotypes of CD45RO+ memory T cell subsets generated upon stimulation with different ICAM lig-
ands and CD3/CD28. (A) Surface phenotype of naïve CD4+ T cells after 14 days of stimulation with CD3/CD28, ICAM-1/
CD3/CD28, ICAM-2/CD3/CD28, or ICAM-3/CD3/CD28 at 10, 100, and 1000 ng. CD4+ T cells were assessed for expression 
of CD45RO and CD11a. (B) Quantitation of the frequency distribution of the generated memory CD4+ T cell subsets was 
assessed on a fixed acquisition of 10,000 CD3+CD4+ T cells. Gated sections (as presented in Fig. 5A) were computed and are 
presented in a color-stacked bar graph: CD45RO-CD11adim (red), CD45RO+CD11adim (orange), CD45RO+CD11aBr (green), 
and CD45RO-CD11aBr (blue). (C) CD27 expression of CD45RO+CD11aBr and CD45RO-CD11aBr naïve CD4+ T cells stimu-
lated with CD3/CD28, ICAM-1/CD3/CD28, ICAM-2/CD3/CD28, or ICAM-3/CD3/CD28 for 14 days. Flow cytometry plots 
are representative of one donor. Assay was repeated with material from 8 donors.
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CD4+CD45RO+CD11abrCXCR3+ cells was greatest with
CD3/CD28 plus ICAM-2, however, all ICAM treatments
displayed greater frequencies of CXCR3 expression than
cells treated with CD3/CD28 alone (Fig. 6A). These results
indicate that distinct memory cell subsets, as demarcated
by surface markers CD11a, CD27, and CXCR3 can be gen-
erated by the ICAM ligands in the presence of CD3/CD28.
Importantly, since CXCR3 is a receptor for IP10 (inter-
feronγ-inducible 10 kDa protein), Mig (monokine
induced by interferonγ), and I-TAC (interferon-inducible
T cell α-chemoattractant), and a major participant in Th-1
induced inflammation [31], the elevated expression in
CD3/CD28/ICAM-2 stimulated cells suggest these cells
are poised to be responsive to TH1 CXC ligands.
To gain further insight into the functional capabilities of
the long-term differentiated CD4 T cells generated with
CD3/CD28 and ICAM ligands, 21 day differentiated cells
were subjected to a transmigration assay to determine
chemotactic capabilities. The specific migration of each
subset was expressed as a percentage of the number of
those cells in the original starting population. The migra-
tion pattern of CD4+CD45RO+CD11abrCD27+ was simi-
lar for all chemokines tested (SDF-1, Rantes, MIP3β,
MIP1β, MIP1α, MCP-1, IP-10, and IL-8) for the CD3/
CD28 plus ICAMs, contrasting the CD3/CD28 treatment
alone (Fig. 6B). However, only the CD3/CD28 plus
ICAM-3 treatment produced
CD4+CD45RO+CD11aBrCD27- cells that transmigrated
(Fig. 6B). Quantifying the absolute counts of the transmi-
grated populations identified that only CD3/CD28 plus
ICAM-3 produced CD4+CD45RO+CD11aBrCD27- that
were functionally responsive to chemotaxis for all agents
tested (Fig. 7A). Therefore, only the CD3/CD28 plus
ICAM-3 stimulation generated a highly differentiated
memory CD4+ T cell subset that was functionally respon-
sive to properties exhibited by terminally differentiated
CD4+ memory T cells in vivo.
To more directly elucidate the underlying molecular
mechanisms of the highly differentiated CD4+ memory T
cell subsets, we analyzed intracellular phosphorylation of
JNK, p38 and Erk1/2 in response to IP-10, MIP1β, and
MIP3α. Phospho-p44/42 was induced in all treatments of
IP-10, MIP1β, and MIP3α only in the CD3/CD28/ICAMs
stimulated cells (Fig. 7B). Phospho-p38 and phospho-
JNK was enhanced for CD3/CD28 plus ICAM-3 for MIP1β
stimulation in contrast to the other CD3/CD28/ICAMs
(Fig. 7B). A higher frequency of dually phosphorylated
JNK and p44/42 CD4+CD45RO+CD11aBr  cells were
observed when CD3/CD28 plus ICAM-3 generated cells
were stimulated with MIP3α (Fig. 7C). Intriguingly, cells
generated with CD3/CD28 or with CD3/CD28 plus
ICAM-1 displayed lower levels of JNK and p44/42 phos-
phorylated cells in response to MIP3α stimulation than
CD3/CD28 plus ICAM-2 or CD3/CD28 plus ICAM-3
stimulations (Fig. 7C). These results were reproduced
across different donors (Fig. 7D). These results suggest
that ICAM-3 and CD3/CD28 co-stimulation generated a
highly differentiated memory T cell subset that is func-
tionally distinct from and differentially responsive to
immunomodulatory agents compared to cells generated
with either ICAM-1 or ICAM-2 and CD3/CD28.
Discussions and Conclusion
In this report we present evidence that the ICAM ligands
of LFA-1 induce distinct signaling activation events that
have functional consequences for human CD4+ memory
T cell differentiation in vitro. We undertook a comprehen-
sive approach to dissect the differences amongst cells
treated with the ICAM ligands within the context of T cell
activation and differentiation. Using multiparameter sur-
face phenotyping in conjunction with intracellular phos-
pho-protein profiling, extracellular cytokine profiling,
and chemotactic functional assays, we found that distinct
CD4+ memory T cell subsets were generated when cells
were stimulated with ICAM-3/CD3/CD28 and ICAM-2/
CD3/CD28, and contrasted those generated by ICAM-1/
CD3/CD28, or CD3/CD28 stimulation.
Intracellular activation of p38 and Erk1/2 was sensitive to
the ICAM ligand used in combination with CD3/CD28
stimulation. Both p38 and Erk1/2 are known to integrate
signals to regulate both mitogenesis and differentiation in
various cellular systems and these two MAPKS are integral
for T cell development, activation, and differentiation
[32,33]. Single cell quantitation of the intracellular phos-
phorylation of p38 and the ratiometric measurement of
phosphorylated Erk1/2 revealed that the integration of
CD3, CD28 and LFA-1 were dependent on the LFA-1 lig-
and used for stimulation. We surmise that sub-optimal
levels of active Erk1/2 result in the first stages of T cell acti-
vation (initial cell division, activation marker expression,
and cytokine production), but are not sufficient to dictate
full conversion into highly differentiated T cells. This can
be concluded since not all ICAM stimulations promoted
the full conversion of CD45RA+ to CD45RO+ cells in T cell
differentiation assays in vitro. Intriguingly, when the ICAM
ligands were tested in combination, ICAM-1 and ICAM-2
enabled cell progression to the CD45RA+CD45RO+ stage,
whereas ICAM-1 stimulation alone did not allow cells to
pass the CD45RA+ stage. Also, the combination of ICAM-
1 and ICAM-3 enabled some cells in the population to
progress to the full CD45RO+  stage, whereas neither
ICAM-1 nor ICAM-3 alone allowed progression past the
CD45RA+ stage (Fig. 3). These observations suggest a com-
plex regulation of signaling events by LFA-1 dependent on
the combination of ligands present. Although ICAM-1
and ICAM-3 have been observed at the immunological
synapse in separate studies [34,35], the dynamic interac-BMC Immunology 2007, 8:2 http://www.biomedcentral.com/1471-2172/8/2
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Generation of CD45RO+ memory T cell subsets with distinct CXCR3 expression and functional characteristics Figure 6
Generation of CD45RO+ memory T cell subsets with distinct CXCR3 expression and functional characteris-
tics. (A) Chemokine surface receptor profiling of naïve CD4+ T cells stimulated with CD3/CD28, ICAM-1/CD3/CD28, ICAM-
2/CD3/CD28, or ICAM-3/CD3/CD28 for 7 days. Cells were gated on either CD4+CD45RA+ (top row) or CD4+CD45RO+ 
(bottom row). Highlighted subset contour plots identify expression pattern and frequency for CXCR3 and CD11a on 
CD4+CD45RO+ cells. Flow cytometry plots are representative of triplicate measures from two individual donors. Repeating 
assay at lower concentrations of ICAM concentration showed no difference (data not shown). (B) Specific transmigration of 
naïve CD4+ T cells after 21 days of stimulation. Cells were differentiated in vitro with CD3/CD28, ICAM-1/CD3/CD28, 
ICAM-2/CD3/CD28, or ICAM-3/CD3/CD28 and subjected to a transmigration assay using specific chemoattractant molecules 
(as noted in Fig.). After 24 hours, cells were immunophenotyped for CD4+CD45RO+CD11aBrCD27+ (top panel) and 
CD4+CD45RO+CD11aBrCD27- (bottom panel). Experiments were reproduced with cells from two different donors. Trans-
migration experiments were repeated in duplicates with material from three donors. tTest calculations were performed and 
indicated in the table insert, with p < 0.05 being significant.
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ICAM ligands induce distinct functional properties in ex vivo generated memory CD4+ T cells Figure 7
ICAM ligands induce distinct functional properties in ex vivo generated memory CD4+ T cells. (A) Analysis of 
transmigrated memory cell subsets after 21 days of stimulation with CD3, CD3/CD28, ICAM-1/CD3/CD28, ICAM-2/CD3/
CD28, or ICAM-3/CD3/CD28. Frequency of subset specific transmigration is presented on the axis. Inset is display of the 
CD4+CD45RO+CD11aDim and CD4+CD45RO+CD11aBr populations on CD27 expression. (B) Intracellular activation of 
phospho-JNK, phospho-p38, and phospho-p44/42 upon IP-10, MIP1β, or MIP3α stimulation (100 ng, 15 min) CD4+ T cells 
stimulated for 21 days with CD3/CD28, ICAM-1/CD3/CD28, ICAM-2/CD3/CD28, or ICAM-3/CD3/CD28. Fluorescent inten-
sities are shown relative to CD3/CD28 and normalized to a Log2 scale. (C) Phospho-subset frequency for phospho-p44/42 and 
phospho-JNK populations for the MIP3α stimulated cohort as described above. Experiments were reproduced with cells from 
two different donors. Transmigration experiments were repeated in duplicates with material from two donors. (D) Quantita-
tion of percent phospho-p44/42/phospho-JNK cells of the 21 day differentiated CD4+CD45RO+CD11aBr subset as stimulated 
by MIP3α from two different donors.
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tion of among the three ICAM ligands at the synapse has
not been reported. Thus, thee results presented here sug-
gest that the combinatorial integration of ICAM ligand
interactions with LFA-1 have important and unexpected
functional consequences for T cell biology.
Both ICAM-2/CD3/CD28 and ICAM-3/CD3/CD28 stim-
ulations had higher Erk1/2 signaling thresholds and cor-
related with less activation of caspase-3 and higher levels
of intracellular BCL2 levels than other treatments. These
stimulation regimes also generated highly differentiated
CD4+ memory T cells that were functionally responsive to
chemotactic agents. In murine models, Erk1/2 has been
implicated in regulation of both positive and negative
selection of developing T cells [33,36-38]. This develop-
mental process is dependent on activation-induced cell
death mechanisms that remove autoreactive T cells from
the periphery. Improper elimination of autoreactive T
cells leads to several forms of autoimmunity[39,40]. Inhi-
bition of programmed cell death is also a prominent fea-
ture of various forms of T and B cell lymphomas [41,42].
The relationship between intracellular signaling thresh-
olds and cell death mechanisms in human naïve CD4+ T
cells are currently not understood, however, the method-
ologies employed in this study can be used to resolve the
interconnectedness of these two processes.
Activation of CD4 T lymphocytes in the presence of spe-
cific cytokines causes differentiation into distinct effector
TH subsets with different immunoregulatory properties.
TGFβ1 is an immunosuppressive cytokine that has been
observed to suppress the proliferative response of
CD4+CD45RO+ lymphocytes [43] and inhibit the produc-
tion of IFNγ [44]. In our experiments, it was noted that
CD3/CD28 and CD3/CD28/ICAM-1 stimulation gener-
ated the highest levels of TGFβ1 and consequently, these
two stimulation regiments also had the lowest frequency
of IFNγ producing T cells (Fig. 4C) and suppressed pro-
duction of CD4+CD45RO+ memory cells (Fig. 5B). There-
fore, the enhancement in signaling imparted by LFA-1
upon binding ICAM-2 or ICAM-3 in human CD4+ T cells
can attenuate T cell differentiation. Mechanistic under-
standing on how LFA-1 regulates phosphatase activities
may shed some light as to how ligand binding correlates
with differential intracellular activities and subsequent
cellular outcomes.
A clear understanding of the distinctive tissue distribu-
tions of the ICAM ligands, and their roles in determining
function of T cells, in the human system has not been
completely resolved. ICAM-1 (CD54) has a wide tissue
distribution on both hematopoietic and non-hematopoi-
etic cells, can be up regulated upon cellular activation and
is viewed as the prominent LFA-1 ligand at the immuno-
logical synapse in model systems of cell-to-cell contact
and of leukocyte rolling [3]. ICAM-1 is closely related to
ICAM-3 (CD50), which is constitutively expressed at high
levels on leukocytes and epidermal dendritic Langherans
cells and can also be up regulated upon activation on
endothelial cells. These two ICAMs contrast with ICAM-2
(CD102), which is broadly expressed on leukocytes and
constitutively expressed at high levels on vascular
endothelium and is not up regulated upon cellular activa-
tion [45]. Interestingly soluble forms of the ICAMs exist in
human blood and have been correlated with disease indi-
cations [46,47]. The physiological significance of soluble
ICAMs in the blood is unknown; however, given the
results presented here, one can surmise that the presence
of extracellular LFA-1 ligands might potentiate the
response of T cell activation and subsequent differentia-
tion.
It is interesting to note that ICAM-1 is the only LFA-1 lig-
and that has been studied extensively for its adhesive con-
tribution in the immune synapse formation and has been
previously implicated to promote increased TH1 differen-
tiation [43,48]. From biophysical experiments, ICAM
affinity interactions have been calculated using recom-
binant proteins to suggest ICAM-1 has the highest affinity
for the LFA-1 receptor [49]. However, more recent studies
have suggested a dynamic conformational change of LFA-
1 that has been attributed to the discrepancy of 2D and 3D
off-rate measurements and requires adjustment of the lig-
and and receptor densities to accurately estimate an affin-
ity constant [50].
Because structurally, the ICAMs exhibit geometrical differ-
ences, with ICAM-1 being the only ICAM reported to
require dimerization for activity [51-54] our data suggest
further experimentation is necessary to account for the
biological differences observed in human memory T cell
differentiation in vitro. At present only one published
study using ICAM-1-/- splenic antigen presenting cells has
demonstrated a delayed response in generating patho-
genic CD4+ effector cells in a murine model of diabetes
[55], however a comparative study of the different ICAMs
in disease models has not demonstrated. Future work will
require follow-up in T cell stimulation by selective ICAM-
deficient antigen presenting cells in both murine models
and human systems.
When T cells interact with antigen presenting cells (APC),
these cells display multiple ICAM ligands at their surface.
It has been observed that one T cell can interact with sev-
eral APCs [56], thereby altering the potential density of
locally present interacting LFA-1 ligands. Thus, it is plau-
sible that LFA-1 on any given CD4+ T cell is presented
with multiple opportunities to interact with one or more
of its ligands, and that the density of ligand interaction
governs the intracellular events regulated by LFA-1. ThisBMC Immunology 2007, 8:2 http://www.biomedcentral.com/1471-2172/8/2
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coupled with the dynamic range of in vivo peptide-MHC
interactions and the number of co-stimulatory molecular
interactions warrants further studies into the combinato-
rial matrix of influential intracellular signaling thresholds
that dictate T cell fates. The studies presented here show
clearly that interaction simultaneously with different LFA-
1 ligands gives rise to different outcomes during memory
T cell generation in vitro. Thus, cells are capable of inter-
preting the presence of distinct ICAM molecules presented
simultaneously and collating a response that is distinct
from their response to any individual ICAM. Whether this
is due to action upon all receptors simultaneously or dif-
ferent ICAM ligands, when presented in combination,
seek out distinct LFA-1 receptors, with at present
unknown modifications or abilities, on the cell surface
remains to be determined.
We previously demonstrated that LFA-1 lowers T cell acti-
vation thresholds[20] and we recently showed that signal-
ing through LFA-1 can activate human NK cells[57]. The
present work demonstrates that LFA-1 signaling mecha-
nisms can potentiate TH1 development and that the com-
binatorial integration of ligand dependent LFA-1
signaling regulates the development of memory T cell
development. Our results also illustrate that quantifiable
intracellular signaling thresholds, as imposed by LFA-1,
can regulate T cell commitments. We expect that such
thresholds, like Erk1/2 phosphorylation, serve as signal-
ing checkpoints that regulate TH1/TH2 development.
These may be important in T cell-dependent autoimmune
diseases, including rheumatoid arthritis and multiple scle-
rosis, where aberrant cell activity leads to pathological
outcomes. The identity of such checkpoints, and the regu-
latory kinases and adapter proteins that instruct these
processes, may serve as novel areas for pharmaceutical
intervention for controlling autoreactive T cells in autoim-
mune diseases and possibly in T-cell cancers
Methods
Immunological and Chemical Reagents
Anti-human CD3, CD4, CD45RA, CD45RO, CD11a, and
CD27 direct conjugates (FITC/PE/PercP/PerCPCy5.5/
APC/Pe-Cy7/APC-Cy7), cleaved caspase-3-PE, BCL2-
FITC, and CD128b, CXCR3, CXCR5, CCR9, CCR5,
CXCR4, CCR7, CCR6, CCR1, CCR2, CCR4, CDw128 (all
on AX647) were obtained from PharMingen. ICAM-2
mAb and ICAM-2-FITC were from IC2/2 Research Diag-
nostics. Phospho-specific antibodies to p44/42 (T201/
Y202), Gsk3β (Y279), Ikkα (S32/36), PLCγ1 (Y783), Lck
(Y505), Zap70 (Y319), p38 (T180/Y182), Stat1 (Y701),
Stat3 (Y705), Stat3 (S727), Stat5 (Y694), Stat6 (Y694),
and PKA (S114) conjugated directly to Alexa dyes were
from BD-Biosciences. TruCount beads were from BD-
Immunocytometry systems. LFA-1 antibody clones TS1/
22 and TS1/18 were obtained from the Developmental
Hybridoma Studies Bank. Protein and chemical reagents
used (and vendors) included fluorescein isothiocyanate
(FITC, Pierce), Alexa Fluor dye series 488, 546, 568, 647,
680, 700 and CFMDA (Molecular Probes). PMA, ionomy-
cin, and propidium iodide were purchased from Sigma.
Recombinant human ICAM-1-FC, ICAM2-FC, ICAM3-FC
were from R&D Systems. Recombinant cytokines IL-2, IL-
4, IL-6, IL-10, IL-12, IFNγ, and TNFα were obtained from
PharMingen. Recombinant chemokines IP-10, MIB1β,
and MIP3α were from R&D Systems. Secondary antibod-
ies to mouse and rabbit IgG were obtained from Santa
Cruz Biotechnologies. Control treatments consisted of
mouse IgG (for antibodies), 1% BSA (for proteins), or
0.01% DMSO vehicle (for chemicals). Secondary
crosslinkers were evaluated and optimized for stimula-
tions.
Cell Culture
Human peripheral blood lymphocytes were obtained by
Ficoll-plaque density centrifugation (Amersham Pharma-
cia) of whole blood from healthy donors (Stanford Blood
Bank) and depleted for adherent cells. Magnetically acti-
vated cell sorting (Dynal) was used to negatively isolate
naïve CD4+ cells for studies as indicated. Human cells
were maintained in RPMI, 5% human sera AB (Irvine Sci-
entific), and 1% penicillin-streptomycin glutamate
(PSQ). Blood from 42 donors were used for these studies.
U-bottom Nunc-Immuno plates with MaxiSorp surface
were used for immunology assays. Standard ELISA tech-
niques were used to coat plates, briefly, 200 µL of ligands
at concentrations of 0.01–1 µg in PBS, pH7.4 were added
to wells and incubated at 4°C overnight. For comparative
purposes, stoichiometric ratios of either two or three anti-
body or ligand were maintained constant by equal mixing
prior to adsorption. Excess antigen coating solutions were
removed and plates were blocked with complete media
for 30 min before being incubated with cells. The Max-
iSorp surface is a modified, highly charged polystyrene
surface with high affinity to molecules with polar or
hydrophilic groups and has a high binding capacity for
proteins, including globular antibodies in proper orienta-
tion. Maximum binding capacity in a monoloayer is 650
ng/cm2.
Flow Cytometry
Intracellular and extracellular staining was performed as
described[58]. Intracellular probes for active kinases were
made by conjugating phospho-specific antibodies to the
Alexa Fluor dye series as described [58, 59]. Kinetic analy-
ses were performed by direct application of fixation buffer
in time-synchronized 96-well plates maintained at 37°C.
200 µL of 2% paraformaldehyde was added to 100 µL of
0.5 × 106 cells, stimulated as indicated, and the mixture
was pipetted up and down three times to ensure even mix-
ing. Plates were kept in a 37°C water bath during the proc-BMC Immunology 2007, 8:2 http://www.biomedcentral.com/1471-2172/8/2
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ess. Fixation was performed for 10 min at 37°C, and
plates were then centrifuged (1500 RPM, 5 min, 4°C) and
processed for flow cytometric staining. Flow cytometry
data are representative of at least three independent exper-
iments. Figure legends indicate specific replicate and
donor repeatability. Intracellular cytokine staining was
performed as suggested by manufacturer of intracellular
IFNγ-APC stain (BD-Pharmingen). The proliferation assay
was performed on sorted naïve CD4+ T cells labeled with
1  µM 5-carboxymethylfluorescein diacetate (CMFDA,
Molecular Probes) in PBS for 5 min at 37°C. The mixture
was added to coated plates (2 × 105 cells/well) in RPMI
medium 1640 containing 5% human AB sera. After 96
hrs, the cells were stained for CD4 and analyzed. Absolute
cell counts were done using TruCount beads. Data was
collected on a FACSCalibur (four-color) using Cellquest
software or an LSRII (12-color) machine with DiVA soft-
ware (Becton-Dickinson) and analyzed using Flowjo soft-
ware (Treestar). Clustering analysis, heatmap
visualization, principle component analysis, and scatter
plot analysis was performed in Spotfire software. Compar-
ison algorithms used for data analysis were supported by
Flowjo. Two algorithms (Overton and SED) were used to
calculate the percentage of positive cells found in the sam-
ple and not in the control. Two algorithms (Kolmogorov-
Smirnov (K-S) and Probability Binning (Chi(T) or PB)
were used to determine the statistical difference between
samples. The PB algorithm has been shown to detect
small quantitative differences between two populations.
Multiplex bead assays
Cytokine detection was performed using either Cytomet-
ric Bead Arrays (CBA, PharMingen) to detect TH1/TH2
cytokines (IL-2, IL-4, IL-5, IL-6, IL-10 TNFα, and IFNγ) on
a FACSCalibur machine or using Beadlyte multiplex kits
(Upstate Biotechnologies) to detect (IL-2, IL-3, IL-4, IL-5,
IL-6, IL-7, IL-9, IL-10, IL-12, IL-13, IL-15, TNFα, IFNγ,
MIP1α, Eotaxin, MCP, and GMCSF) on a Luminex
machine. The apoptosis CBA kit was from PharMingen.
Protocols suggested by the manufacturers were used.
Transmigration assay
Cells were placed (0.25 × 106 cells in 100 µL) in the upper
well of 24-well transmigration chambers (5 µm pore,
Transwell, Costar Corp.) 100 ng SDF-1, Rantes, MIP3β,
MIP1α, MIP1β, MCP-1, IP-10, or IL-8 (in 0.5 µL media)
was then added to the lower well. Plates were incubated
for 24 hrs at 37°C and cells that migrated to the lower
chamber were counted using TruCount beads.
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